PressFebruary 26, 2026 Definium reports full-year 2025 results with $411.6M cash and three 2026 Phase 3 readouts on track
PressFebruary 26, 2026 AtaiBeckley reports positive Phase 2a topline for EMP-01 (oral R-MDMA) in social anxiety disorder
PressFebruary 23, 2026 PharmAla to supply Amsterdam UMC with LaNeo MDMA and develop single-capsule stability data
PressFebruary 23, 2026 FDA grants Breakthrough Therapy Designation to Reunion's luvesilocin (RE104) for postpartum depression
PressFebruary 17, 2026 Compass hits primary endpoint in second Phase 3 psilocybin trial, giving it two positive pivotal studies
PressFebruary 9, 2026 Clearmind reports additional positive safety data for CMND-100 in alcohol use disorder
PressFebruary 4, 2026 Trump administration officials strip Compass psilocybin from FDA fast-track voucher list
PressJanuary 26, 2026 Optimi Health completes first 2026 production run of MDMA and psilocybin capsules
PressJanuary 12, 2026 MindMed unveils full rebrand as Definium Therapeutics, spotlighting late-stage LSD pipeline
